4
H index
1
i10 index
56
Citations
James Mason : Citation Profile
| RESEARCH PRODUCTION: 18 Articles 6 Papers RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
29 years (1993 - 2022). Relations with other researchers
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with James Mason. | Is cited by:
| Cites to:
|
Main data
Where James Mason has published?
| Journals with more than one article published | # docs |
|---|---|
| PharmacoEconomics | 4 |
| Health Policy | 4 |
| Social Science & Medicine | 4 |
| PLOS ONE | 2 |
| Health Economics | 2 |
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Working Papers / Centre for Health Economics, University of York | 6 |
Recent works citing James Mason (2025 and 2024)
Year  | Title of citing document |
|---|---|
| 2024 | Exploring space and practices of control in long-term residential care violence prevention strategies. (2024). Novek, Sheila ; Herron, Rachel V ; Funk, Laura ; Aubrecht, Katie ; Spencer, Dale ; Kelly, Christine. In: Social Science & Medicine. RePEc:eee:socmed:v:355:y:2024:i:c:s0277953624005446. Full description at Econpapers || Download paper |
Works by James Mason:
| Year | Title | Type | Cited |
|---|---|---|---|
| 1995 | The DH register of cost-effectiveness studies: a review of study content and quality In: Working Papers. [Full Text][Citation analysis] | paper | 1 |
| 1995 | Screening for diabetic retinopathy by optometrists: effectiveness and cost-effectiveness In: Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 1998 | NICEly does it: economic analysis within evidence-based clinical practice guidelines In: Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 1999 | Evaluating change in professional behaviour: issues in design and analysis In: Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2002 | Topical preparations for the treatment of psoriasis in primary care: a systematic review In: Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2002 | Optometrist prescribing of therapeutic agents: economic implications for the UK In: Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 1995 | Cost-effectiveness league tables: think of the fans In: Health Policy. [Full Text][Citation analysis] | article | 6 |
| 1997 | Biotechnology: a special case for health technology assessment? In: Health Policy. [Full Text][Citation analysis] | article | 2 |
| 1999 | A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines In: Health Policy. [Full Text][Citation analysis] | article | 3 |
| 2002 | Optometrist prescribing of therapeutic agents: findings of the AESOP survey In: Health Policy. [Full Text][Citation analysis] | article | 0 |
| 1993 | Cost-effectiveness league tables: More harm than good? In: Social Science & Medicine. [Full Text][Citation analysis] | article | 19 |
| 2013 | Creating ‘therapeutic landscapes’ for mental health carers in inpatient settings: A dynamic perspective on permeability and inclusivity In: Social Science & Medicine. [Full Text][Citation analysis] | article | 4 |
| 2013 | Spaces for smoking in a psychiatric hospital: Social capital, resistance to control, and significance for ‘therapeutic landscapes’ In: Social Science & Medicine. [Full Text][Citation analysis] | article | 3 |
| 2013 | Compassionate containment? Balancing technical safety and therapy in the design of psychiatric wards In: Social Science & Medicine. [Full Text][Citation analysis] | article | 6 |
| 2014 | Prophylactic Antibiotics to Prevent Cellulitis of the Leg: Economic Analysis of the PATCH I & II Trials In: PLOS ONE. [Full Text][Citation analysis] | article | 0 |
| 2017 | Agreement between gastrointestinal panel testing and standard microbiology methods for detecting pathogens in suspected infectious gastroenteritis: Test evaluation and meta-analysis in the absence of a reference standard In: PLOS ONE. [Full Text][Citation analysis] | article | 0 |
| 2021 | Multivariate Generalized Linear Mixed-Effects Models for the Analysis of Clinical Trial€“Based Cost-Effectiveness Data In: Medical Decision Making. [Full Text][Citation analysis] | article | 0 |
| 2000 | The Importance of Achieving Additional Drug Benefits at a Reasonable Cost In: PharmacoEconomics. [Full Text][Citation analysis] | article | 0 |
| 2017 | Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Systematic Literature Review In: PharmacoEconomics. [Full Text][Citation analysis] | article | 1 |
| 2018 | Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal In: PharmacoEconomics. [Full Text][Citation analysis] | article | 0 |
| 2019 | Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal In: PharmacoEconomics. [Full Text][Citation analysis] | article | 0 |
| 2022 | The urgent case for stronger climate targets for international shipping In: Climate Policy. [Full Text][Citation analysis] | article | 2 |
| 1995 | Reporting guidelines for economic studies In: Health Economics. [Full Text][Citation analysis] | article | 9 |
| 1996 | Student corner In: Health Economics. [Full Text][Citation analysis] | article | 0 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated February, 4 2025. Contact: CitEc Team